Rubius Therapeutics

Rubius Therapeutics, Inc. is a biotechnology company focused on developing red cell therapeutics (RCTs) aimed at treating patients with severe diseases, including cancer, enzyme deficiencies, and autoimmune disorders. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company is advancing several therapeutic candidates, such as RTX-240 and RTX-224 for cancer treatment, RTX-aAPC for solid and hematological cancers, RTX-321 for HPV-positive tumors, and RTX-T1D for type 1 diabetes. By creating a new class of medicines, Rubius Therapeutics seeks to address significant unmet medical needs through innovative approaches in the field of biotechnology.